Published in New Biol on January 01, 1990
Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell (1999) 5.01
Bacterial peptide chain release factors: conserved primary structure and possible frameshift regulation of release factor 2. Proc Natl Acad Sci U S A (1985) 3.94
Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc Natl Acad Sci U S A (1995) 2.49
The identity of the base following the stop codon determines the efficiency of in vivo translational termination in Escherichia coli. EMBO J (1995) 2.36
Sequence analysis suggests that tetra-nucleotides signal the termination of protein synthesis in eukaryotes. Nucleic Acids Res (1990) 2.20
The signal for the termination of protein synthesis in procaryotes. Nucleic Acids Res (1990) 2.05
The translational termination signal database. Nucleic Acids Res (1993) 1.90
Metabotropic glutamate receptors trigger homosynaptic protein synthesis to prolong long-term potentiation. J Neurosci (2000) 1.89
Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. Ann Rheum Dis (1994) 1.67
Codon bias at the 3'-side of the initiation codon is correlated with translation initiation efficiency in Escherichia coli. Gene (2001) 1.65
Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology (2001) 1.64
Road traffic accidents and diabetes: insulin use does not determine risk. Diabet Med (2008) 1.63
Release factor-dependent false stops are infrequent in Escherichia coli. J Mol Biol (1993) 1.57
TransTerm, the translational signal database, extended to include full coding sequences and untranslated regions. Nucleic Acids Res (1999) 1.52
Metaplasticity: a new vista across the field of synaptic plasticity. Prog Neurobiol (1997) 1.51
Clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index case and extended family. Mayo Clin Proc (1997) 1.49
Inhibition of nitrification in the activated sludge process of sewage disposal. J Appl Bacteriol (1966) 1.49
Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study. Rheumatology (Oxford) (1999) 1.48
Frameshift autoregulation in the gene for Escherichia coli release factor 2: partly functional mutants result in frameshift enhancement. Nucleic Acids Res (1990) 1.41
The role of immediate early genes in the stabilization of long-term potentiation. Mol Neurobiol (1991) 1.41
Early results of infragenicular revascularization based solely on duplex arteriography. J Vasc Surg (2001) 1.39
Autoantibodies in pet dogs owned by patients with systemic lupus erythematosus. Lancet (1992) 1.38
Maintenance of long-term potentiation in rat dentate gyrus requires protein synthesis but not messenger RNA synthesis immediately post-tetanization. Neuroscience (1989) 1.37
Comparison of the ETDRS logMAR, 'compact reduced logMar' and Snellen charts in routine clinical practice. Eye (Lond) (2009) 1.34
Mammalian release factor; in vitro assay and purification. Methods Enzymol (1974) 1.32
The concentration of polypeptide chain release factors 1 and 2 at different growth rates of Escherichia coli. J Mol Biol (1994) 1.30
Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response. Infect Immun (1999) 1.30
Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) (2005) 1.26
Correlations between immediate early gene induction and the persistence of long-term potentiation. Neuroscience (1993) 1.26
Competition between frameshifting, termination and suppression at the frameshift site in the Escherichia coli release factor-2 mRNA. Nucleic Acids Res (1993) 1.26
Translational termination in Escherichia coli: three bases following the stop codon crosslink to release factor 2 and affect the decoding efficiency of UGA-containing signals. Nucleic Acids Res (1998) 1.25
Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med (2000) 1.25
Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol (2004) 1.25
Heterosynaptic metaplasticity in the hippocampus in vivo: a BCM-like modifiable threshold for LTP. Proc Natl Acad Sci U S A (2001) 1.22
The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989-1990. Br J Rheumatol (1993) 1.22
The translational termination signal database (TransTerm) now also includes initiation contexts. Nucleic Acids Res (1994) 1.21
Prokaryotic ribosomes recode the HIV-1 gag-pol-1 frameshift sequence by an E/P site post-translocation simultaneous slippage mechanism. Nucleic Acids Res (1995) 1.21
Two regions of the Escherichia coli 16S ribosomal RNA are important for decoding stop signals in polypeptide chain termination. Nucleic Acids Res (1993) 1.20
The incidence of decreased red blood cell deformability in sepsis and the association with oxygen free radical damage and multiple-system organ failure. Arch Surg (1989) 1.20
Direct recognition of mRNA stop signals by Escherichia coli polypeptide chain release factor two. J Biol Chem (1994) 1.20
A single proteolytic cleavage in release factor 2 stabilizes ribosome binding and abolishes peptidyl-tRNA hydrolysis activity. J Biol Chem (1994) 1.17
The interarm blood pressure difference as predictor of cardiovascular events in patients with hypertension in primary care: cohort study. J Hum Hypertens (2007) 1.16
The requirement for ribosomal proteins L7 and L12 in peptide-chain termination. Proc Natl Acad Sci U S A (1974) 1.16
The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol (2005) 1.15
The Escherichia coli ribosomal protein L11 suppresses release factor 2 but promotes the release factor 1 activities in peptide chain termination. J Biol Chem (1983) 1.15
Alignment of 700 globin sequences: extent of amino acid substitution and its correlation with variation in volume. Protein Sci (1995) 1.14
Interferon induces tryptophanyl-tRNA synthetase expression in human fibroblasts. J Biol Chem (1991) 1.14
Linkage of familial Hibernian fever to chromosome 12p13. Am J Hum Genet (1998) 1.14
Behçet's disease. Postgrad Med J (2000) 1.13
Epoprostenol in systemic capillary leak syndrome. Lancet (1988) 1.11
Primary aortoduodenal fistula in a patient with a history of intravesical therapy for bladder cancer with bacillus Calmette-Guérin: review of primary aortoduodenal fistula without abdominal aortic aneurysm. J Vasc Surg (2001) 1.11
Coculture of endothelial cells and smooth muscle cells in bilayer and conditioned media models. J Surg Res (1997) 1.10
Escherichia coli release factor 3: resolving the paradox of a typical G protein structure and atypical function with guanine nucleotides. RNA (1998) 1.10
Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study. Ann Rheum Dis (1998) 1.08
The translational signal database, TransTerm: more organisms, complete genomes. Nucleic Acids Res (1997) 1.06
Peptidyltransferase inhibition by trichodermin. J Biol Chem (1973) 1.06
Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology (1999) 1.06
Ribosomal proteins cross-linked to peptide chain termination release factor 2. J Biol Chem (1982) 1.04
Normal production of inflammatory cytokines in chronic fatigue and fibromyalgia syndromes determined by intracellular cytokine staining in short-term cultured blood mononuclear cells. Clin Exp Immunol (2003) 1.04
Isolation of a rat mitochondrial release factor. Accommodation of the changed genetic code for termination. J Biol Chem (1987) 1.04
Assessment of Be1 and Be2 cells in systemic lupus erythematosus indicates elevated interleukin-10 producing CD5+ B cells. Lupus (2003) 1.03
Transterm: a database of messenger RNA components and signals. Nucleic Acids Res (2000) 1.02
The ribosomal binding and peptidyl-tRNA hydrolysis functions of Escherichia coli release factor 2 are linked through residue 246. RNA (2000) 1.02
Effect of thalidomide on orogenital ulceration. Br Med J (Clin Res Ed) (1983) 1.02
C reactive protein concentrations in neonates: determination by a latex enhanced immunoassay. J Clin Pathol (1984) 1.02
Correlation between the induction of an immediate early gene, zif/268, and long-term potentiation in the dentate gyrus. Brain Res (1992) 1.01
Wegener's granulomatosis--a review of diagnosis and treatment in 53 subjects. Rhinology (1998) 1.01
Interaction of the release factors with the Escherichia coli ribosome: structurally and functionally-important domains. Biochimie (1992) 1.01
The leader peptides of attenuation-regulated chloramphenicol resistance genes inhibit translational termination. J Bacteriol (1994) 1.00
Biphasic changes in the levels of N-methyl-D-aspartate receptor-2 subunits correlate with the induction and persistence of long-term potentiation. Brain Res Mol Brain Res (1998) 1.00
Prevalence of rheumatoid arthritis and rheumatoid factor in women: evidence for a secular decline. Ann Rheum Dis (1993) 0.99
Effects of zinc and other metal ions on the stability and activity of Escherichia coli alkaline phosphatase. Biochem J (1971) 0.98
Class specific rheumatoid factors in rheumatoid arthritis: response to chrysotherapy and relationship to disease activity. J Rheumatol (1985) 0.98
Abnormal fibrinolytic activity in systemic lupus erythematosus and possible mechanisms. Br J Rheumatol (1988) 0.98
A dynamic competition between release factor 2 and the tRNA(Sec) decoding UGA at the recoding site of Escherichia coli formate dehydrogenase H. EMBO J (2001) 0.98
Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis (1996) 0.97
Influence of guanine nucleotides and elongation factors on interaction of release factors with the ribosome. Proc Natl Acad Sci U S A (1973) 0.97
Recognition of termination codon by release factor in the presence of a tRNA-occupied A site. Evidence for flexibility in accommodation of the release factor on the ribosome. J Biol Chem (1983) 0.97
An improved assay for IgG rheumatoid factor: its value in the diagnosis of rheumatoid arthritis. J Rheumatol (1985) 0.97
Defective fibrinolysis in Behçet's syndrome: significance and possible mechanisms. Ann Rheum Dis (1989) 0.96
Tightly controlled expression systems for the production and purification of Escherichia coli release factor 1. Biochem Int (1990) 0.96
Rapid identification of an A1555G mutation in human mitochondrial DNA implicated in aminoglycoside-induced ototoxicity. J Hum Genet (1999) 0.95
A specific inhibitor of apoptosis decreases tissue injury after intestinal ischemia-reperfusion in mice. J Vasc Surg (1999) 0.94
Mammalian polypeptide chain release factor and tryptophanyl-tRNA synthetase are distinct proteins. EMBO J (1993) 0.94
The ribosomal binding domain for the bacterial release factors RF-1, RF-2 and RF-3. FEBS Lett (1984) 0.94
Are the tryptophanyl-tRNA synthetase and the peptide-chain-release factor from higher eukaryotes one and the same protein? Eur J Biochem (1993) 0.94
A comparative study of treadmill tests and heel raising exercise for peripheral arterial disease. Eur J Vasc Endovasc Surg (1997) 0.94
Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) (2007) 0.93
Rheumatoid factor tests in the diagnosis and prediction of rheumatoid arthritis. Ann Rheum Dis (1986) 0.93